Mohammad Adnan, K. Mohammad, Mohammad Emdad Hossain Manik
{"title":"抗癌药物与他汀类药物联合使用","authors":"Mohammad Adnan, K. Mohammad, Mohammad Emdad Hossain Manik","doi":"10.4172/JBB.1000345","DOIUrl":null,"url":null,"abstract":"Statins are 3-Hydroxy-3-methylgutaryl CoA (HMG CoA) reductase inhibitors and mainly used in cardiovascular diseases. However, they are also widely known for their anticancer activities mediated by antiproliferative, proapoptotic, anti-invasive, and radio sensitizing properties. They are tested alone in several clinical trials for their anticancer activity and the response in not satisfactory due to high dose requirements in humans. Tumor inhibitory concentration of statins is 10-100 μM for different cancer cell lines when tested in vitro. But statins can cause anorexia and death in some individuals if concentration is reached to 20-25 μM in serum. So, there is high risk factor. To avoid these unwanted harmful effects, we can give statins in combination with other chemotherapeutic drugs for synergism. It will reduce the concentration of statins in dosage, and can avoid unwanted toxic effects. When used along with the other chemo therapeutic agents like prenylation inhibitors, NSAIDS and standard chemotherapeutic agents, they have shown much better results at lower doses with little or no toxicity.","PeriodicalId":15184,"journal":{"name":"Journal of Bioequivalence & Bioavailability","volume":"19 1","pages":"463-466"},"PeriodicalIF":0.0000,"publicationDate":"2017-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":"{\"title\":\"Anticancer Agents in Combination with Statins\",\"authors\":\"Mohammad Adnan, K. Mohammad, Mohammad Emdad Hossain Manik\",\"doi\":\"10.4172/JBB.1000345\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Statins are 3-Hydroxy-3-methylgutaryl CoA (HMG CoA) reductase inhibitors and mainly used in cardiovascular diseases. However, they are also widely known for their anticancer activities mediated by antiproliferative, proapoptotic, anti-invasive, and radio sensitizing properties. They are tested alone in several clinical trials for their anticancer activity and the response in not satisfactory due to high dose requirements in humans. Tumor inhibitory concentration of statins is 10-100 μM for different cancer cell lines when tested in vitro. But statins can cause anorexia and death in some individuals if concentration is reached to 20-25 μM in serum. So, there is high risk factor. To avoid these unwanted harmful effects, we can give statins in combination with other chemotherapeutic drugs for synergism. It will reduce the concentration of statins in dosage, and can avoid unwanted toxic effects. When used along with the other chemo therapeutic agents like prenylation inhibitors, NSAIDS and standard chemotherapeutic agents, they have shown much better results at lower doses with little or no toxicity.\",\"PeriodicalId\":15184,\"journal\":{\"name\":\"Journal of Bioequivalence & Bioavailability\",\"volume\":\"19 1\",\"pages\":\"463-466\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-07-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Bioequivalence & Bioavailability\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/JBB.1000345\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bioequivalence & Bioavailability","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/JBB.1000345","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6
摘要
他汀类药物是3-羟基-3-甲基gutaryl CoA (HMG CoA)还原酶抑制剂,主要用于心血管疾病。然而,它们也因其抗增殖、促凋亡、抗侵袭和放射性致敏特性介导的抗癌活性而广为人知。它们在几个临床试验中单独测试了它们的抗癌活性,但由于对人体的高剂量要求,反应并不令人满意。他汀类药物体外抑瘤浓度为10 ~ 100 μM。但当他汀类药物在血清中的浓度达到20 ~ 25 μM时,可引起部分个体的厌食和死亡。所以,这是一个高风险因素。为了避免这些不必要的有害影响,我们可以将他汀类药物与其他化疗药物联合使用以实现协同作用。它将降低他汀类药物的剂量浓度,并可以避免不必要的毒性作用。当与其他化疗药物一起使用时,如戊酰化抑制剂,非甾体抗炎药和标准化疗药物,它们在低剂量下显示出更好的效果,几乎没有毒性。
Statins are 3-Hydroxy-3-methylgutaryl CoA (HMG CoA) reductase inhibitors and mainly used in cardiovascular diseases. However, they are also widely known for their anticancer activities mediated by antiproliferative, proapoptotic, anti-invasive, and radio sensitizing properties. They are tested alone in several clinical trials for their anticancer activity and the response in not satisfactory due to high dose requirements in humans. Tumor inhibitory concentration of statins is 10-100 μM for different cancer cell lines when tested in vitro. But statins can cause anorexia and death in some individuals if concentration is reached to 20-25 μM in serum. So, there is high risk factor. To avoid these unwanted harmful effects, we can give statins in combination with other chemotherapeutic drugs for synergism. It will reduce the concentration of statins in dosage, and can avoid unwanted toxic effects. When used along with the other chemo therapeutic agents like prenylation inhibitors, NSAIDS and standard chemotherapeutic agents, they have shown much better results at lower doses with little or no toxicity.